Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies
Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...
Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging
Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT...
MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III...
Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer
Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor...
Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District
Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event...
Keymed Biosciences’ Stapokibart Filing Accepted for Priority Review in China for Atopic Dermatitis
Keymed Biosciences Inc. (HKG: 2162) has announced that its market filing for stapokibart (CM310), a...
Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement...
Pfizer and CStone Secure NMPA Approval for Sugemalimab, First PD-L1 Inhibitor for ESCC
Pfizer (NYSE: PFE) and CStone Pharmaceuticals (HKG: 2616) have secured market approval from the National...
Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period,...
AbelZeta and AstraZeneca Team Up for Co-Development of GPC3-Targeted CAR-T Therapy
AbelZeta Pharma Inc., a Sino-U.S. biotech firm based in Rockville, Maryland, and Shanghai, has announced...
Shanghai Henlius Partners with China Resource Medicine to Enhance Product Accessibility
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic partnership with China Resource Medicine...
Medtronic Exits $738 Million Deal to Acquire EOFlow Amid Regulatory and Legal Challenges
U.S.-based Medtronic plc has announced its withdrawal from a previously agreed deal to fully acquire...
AK Medical Secures NMPA Approval for Advanced 3D-Printed Hip Prosthesis Component
China-based AK Medical Holdings Ltd (HKG: 1789) has announced that it has received market approval...
Bio-Thera Secures FDA Approval for Avzivi, a Biosimilar to Roche’s Avastin
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received market approval from the...
Mabwell Secures NMPA Approval for Phase III Study of ADC 9MW2821 in Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it has received approval from...
HutchMed’s Sovleplenib Set for Priority Review in China for Chronic Immune Thrombocytopenia
China’s Center for Drug Evaluation (CDE) has indicated that HutchMed (China) Ltd (NASDAQ: HCM; HKG:...
Trinomab’s TNM002 Antitetanus Monoclonal Antibody Filing Accepted for Review in China
China’s Center for Drug Evaluation (CDE) has accepted Trinomab Biotech Co., Ltd.’s market approval filing...
BMS Broadens Scope of IMID Collaboration, Aiming for Deeper Insights into Sjögren’s and Atopic Dermatitis
Bristol Myers Squibb (BMS; NYSE: BMY) has expanded its 2016 partnership with IMIDomics, broadening the...
Eli Lilly Seeks Approval for Pirtobrutinib in China for Relapsed Mantle Cell Lymphoma
Eli Lilly (NYSE: LLY) has submitted a marketing approval application for pirtobrutinib, an oral, non-covalent...
AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion, Strengthening Neuroscience Portfolio
AbbVie (NYSE: ABBV) has announced its agreement to acquire Cerevel Therapeutics (NASDAQ: CERE) for approximately...